PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2104570
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2104570
Blood Collection Tubes for Liquid Biopsy Market size was valued at US$ 160.2 Million in 2025, expanding at a CAGR of 19.3% from 2026 to 2033.
Blood collection tubes for liquid biopsy are specially designed evacuated phlebotomy tubes that are to be used for the stabilization of unstable blood-based cancer markers in the laboratory. Blood-based cancer markers are circulating tumor cells and cell-free DNA, and they are to be used for performing molecular diagnostic tests once collected. The typical structure of a collection tube includes a vacuum-sealed evacuated tube, which can be made of either glass or plastic materials; a pierced stopper, which is colored; and chemical reagents. These help maintain the viability of biological components in collected specimens until the necessary analysis is done for an accurate diagnosis.
Blood Collection Tubes for Liquid Biopsy Market- Market Dynamics
Growing preference for noninvasive or minimally invasive tests to Propel Market Demand
The growing preference for noninvasive or minimally invasive tests in the blood collection tubes for the liquid biopsy market. Continuous demand for convenient and easy testing procedures with little pain for the patients has fueled the growth of the market. Better diagnosis and disease management can be made through such procedures. For example, based on the study released in 2025 in the National Center for Biotechnology Information (NCBI), the growing preference for non-invasive or minimally invasive testing is becoming more prevalent. The multiple biomarker-based tests involving blood, stool, and urine gave high sensitivity and specificity levels of greater than 90 and 85 percent, respectively. Therefore, the trend is continuously fueling the growth of the blood collection tubes for the liquid biopsy market.
The Global Blood Collection Tubes for Liquid Biopsy Market is segmented on the basis of Product, Material, Application, End User, and Region.
Based on the product, the CTC Tubes segment is anticipated to register steady growth in the blood collection tubes for liquid biopsy market due to the increasing use of circulating tumor cell testing in cancer screening, diagnosis, and prognosis. In May 2025, F. Hoffmann-La Roche Ltd. Collaborated with Broad Clinical Labs to incorporate the company's Sequencing by Expansion (SBX) technology for the development of an innovative solution for next-generation liquid biopsies and genomics workflows by enhancing the sequencing efficiency, scale, and precision for clinical diagnostics. This innovation is expected to propel the adoption of CTC tubes for liquid biopsies.
Blood Collection Tubes for Liquid Biopsy Market- Geographical Insights
North America accounts for a substantial share in the Blood Collection Tubes for Liquid Biopsy market because of the availability of a well-established infrastructure, key market participants, and advanced technologies. For example, in 2025, as per the research article on "Enhancing Diagnostic Infrastructure Through Innovation-Driven Technological Capacity in Healthcare" by NIH.gov, the USA will continue to employ the use of AI-based imaging, molecular diagnostic tests, and point-of-care testing, as it is required to utilise laboratory tests efficiently and effectively to diagnose patients, since almost 70% of the decision-making process is based on the results of laboratory tests. The diagnostics of blood consume about 2-3% of the entire budget of the healthcare industry yet bring many advantages. These factors collectively reinforce North America's leadership in the global Blood Collection Tubes for Liquid Biopsy market.
U.S Blood Collection Tubes for Liquid Biopsy Market- Country Insights
The U.S. liquid biopsy market will be driven by factors like an increase in cancer incidences, increased investment in the development of advanced technology for cancer diagnosis, and the presence of leading companies in the market. For instance, in June 2026, according to the U.S. Centres for Disease Control and Prevention (Gov.), the United States Cancer Statistics (USCS) programme reported a total of 36.7 million new cancer cases reported. The USCS database contains records from all 50 states as well as from the District of Columbia and covers 100 per cent of the US population. In addition to this, there would be an ongoing increase in the incidence of cancer cases and an ageing population, which will create rising concerns regarding the treatment of cancer. Hence, there will be more concerns about the issue of cancer treatment.
Key companies operating in the Blood Collection Tubes for Liquid Biopsy Market, including MagBio Genomics Inc., Zymo Research Corporation, Apostle Sciences, QIAGEN NV, and Greiner Bio-One International GmbH, are concentrating their efforts on innovations within the blood collection technology, ensuring better circulating biomarker preservation. In Nov 2025, Zymo Research Corporation partners with Biomoal to offer next-generation sequencing and epigenetics workflows. Partnerships help in improving methylation analysis and also help in offering advanced molecular testing options through the concept of liquid biopsy. These strategic initiatives are accelerating innovation and strengthening the accuracy and adoption of liquid biopsy diagnostics.
In January 2026, QIAGEN N.V. announced its commercialisation strategy for 2026, which is geared towards launching new molecular diagnostic and automation platforms that are centred around their three growth drivers, which include precision medicine, oncology, and development of liquid biopsies.